Chemoimmunotherapy that utilizes the immunomodulatory effect of chemotherapeutics has shown great promise for treating poorly immunogenic solid tumors. However, there remains a significant room for improving the synergy between chemotherapy and immunotherapy, including the efficient, concurrent delivery of chemotherapeutics and immunomodulators into tumors. Here, we report the use of metabolic glycan labeling to facilitate cancer-targeted delivery of liposomal chemoimmunotherapy. 4T1 triple-negative breast cancer cells can be metabolically labeled with azido groups for subsequently targeted conjugation of dibenzocycoloctyne (DBCO)-bearing liposomes loaded with doxorubicin and imiquimod (R837) adjuvant efficient click chemistry. The encased doxorubicin can induce the immunogenic death of cancer cells and upregulate the expression of CD47 and calreticulin on the surface of cancer cells, while R837 can activate dendritic cells for enhanced processing and presentation of tumor antigens. Targeted delivery of liposomes encapsulating doxorubicin and R837 to 4T1 tumors, enabled by metabolic glycan labeling and click chemistry, showed the promise to reshape the immunosuppressive tumor microenvironment of solid tumors. This cancer-targetable liposomal chemoimmunotherapy could provide a new approach to improving conventional chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626969 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.1010021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detachable Cyclic Poly(ethylene glycol)-Embedded Choline Phosphate Liposome Used for Long-Acting and Accurate Cancer Chemo-Immunotherapy with High Security.
ACS Appl Mater Interfaces
December 2024
Key Laboratory of Polyoxometalate and Reticular Material Chemistry of Ministry of Education, School of Chemistry, Northeast Normal University, Changchun 130024, China.
Liposomes have attracted attention in biomedicine and pharmacy for their benefits including reduced toxicity, extended pharmacokinetics, and biocompatibility. However, their limitations include susceptibility to blood clearance, rapid disintegration, and lack of functionality, restricting their further applications. To address these challenges, inspired by the unique topological features of cyclic polymers and the specific binding property of the choline phosphate (CP) lipid, dipole-dipole interactions between CP molecules are utilized to create a detachable cyclic PEG-embedded CP liposome (d-cycPEG-lipo).
View Article and Find Full Text PDFColon-specific controlled release of oral liposomes for enhanced chemo-immunotherapy against colorectal cancer.
Acta Pharm Sin B
November 2024
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
A colon-specific drug delivery system has great potential for the oral administration of colorectal cancer. However, the uncontrollable fate of liposomes makes their effectiveness for colonic location, and intratumoral accumulation remains unsatisfactory. Here, an oral colon-specific drug delivery system (CBS-CS@Lipo/Oxp/MTZ) was constructed by covalently conjugating spores (CBS) with drugs loaded chitosan (CS)-coated liposomes, where the model chemotherapy drug oxaliplatin (Oxp) and anti-anaerobic bacteria agent metronidazole (MTZ) were loaded.
View Article and Find Full Text PDFHarnessing the Engineered Probiotic-Nanosystem to Remodulate Tumor Extracellular Matrix and Regulate Tumor-Colonizing Bacteria for Improving Pancreatic Cancer Chemo-Immunotherapy.
Small
November 2024
Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan, University, Wuhan, 430072, P. R. China.
Poor chemotherapy efficacy in pancreatic cancer is attributed to limited drug permeation caused by the dense extracellular matrix (ECM) and drug degradation induced by tumor-colonizing bacteria. Here, a tumor-targeting probiotic-nanosystem is elaborately designed to remodulate ECM and selectively regulate tumor-colonizing bacteria for improving chemo-immunotherapy against pancreatic cancer. Specifically, drug-loaded liposomes are conjugated with Clostridium Butyricum (CB) via matrix metalloproteinase-2 (MMP-2)-responsive peptide to construct a probiotic-nanosystem.
View Article and Find Full Text PDFIntratumoral lactic acid neutralization strategy for boosting chemoimmunotherapy using liposomal sodium bicarbonate.
Sci Bull (Beijing)
December 2024
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China; Zhongshan Institute for Drug Discovery, Shanghai Institutes of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, Shanghai 201203, China. Electronic address:
Glycolysis-related lactic acid overproduction creates an "ion-trapping" barrier and immunosuppressive tumor microenvironment that compromise effective intratumoral drug delivery and therapy. Therefore, normalization of tumor microenvironment via lactic acid neutralization can be a promising avenue for overcoming this therapeutic hurdle. In this study, the flexible liposomes loaded with sodium bicarbonate (NaHCO@Flip) were used as a nano-adjuvant to boost chemoimmunotherapy.
View Article and Find Full Text PDFA hierarchically acidity-unlocking nanoSTING stimulant enables cascaded STING activation for potent innate and adaptive antitumor immunity.
Theranostics
September 2024
Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750002, China.
Article Synopsis
- Neoadjuvant chemotherapy (NAC) is essential for treating advanced cancers, but improving patient survival remains a challenge due to its limited effectiveness and issues with tumor recurrence after surgery.
- Researchers have developed a new treatment called AUG, a nanoSTING stimulant liposome, which activates the immune response to help shrink tumors before surgery and reduce the chance of cancer returning post-surgery.
- In tests, AUG demonstrated over 90% effectiveness in inhibiting tumor growth and reduced postoperative metastasis by 75% when used alongside immune checkpoint inhibitors, showcasing its potential as a promising neoadjuvant therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!